[go: up one dir, main page]

UY34078A - PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER

Info

Publication number
UY34078A
UY34078A UY0001034078A UY34078A UY34078A UY 34078 A UY34078 A UY 34078A UY 0001034078 A UY0001034078 A UY 0001034078A UY 34078 A UY34078 A UY 34078A UY 34078 A UY34078 A UY 34078A
Authority
UY
Uruguay
Prior art keywords
methods
pharmaceutical compositions
treat cancer
cancer
treat
Prior art date
Application number
UY0001034078A
Other languages
Spanish (es)
Inventor
Rosen Oliver
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34078A publication Critical patent/UY34078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SIN ESCANEO
UY0001034078A 2011-05-17 2012-05-17 PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER UY34078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23

Publications (1)

Publication Number Publication Date
UY34078A true UY34078A (en) 2012-11-30

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034078A UY34078A (en) 2011-05-17 2012-05-17 PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER

Country Status (7)

Country Link
EP (1) EP2709614A4 (en)
JP (1) JP2014513730A (en)
AR (1) AR086444A1 (en)
CA (1) CA2836277A1 (en)
TW (1) TW201309291A (en)
UY (1) UY34078A (en)
WO (1) WO2012158884A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2600855A2 (en) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
UY33740A (en) * 2010-11-18 2012-05-31 Takeda Pharmaceutical METHOD FOR TREATING BREAST CANCER AND OVARIAN CANCER
UA117663C2 (en) 2012-09-26 2018-09-10 Арагон Фармасьютікалз, Інк. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
AU2014241816B9 (en) * 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
MX2008012492A (en) * 2006-03-29 2008-12-12 Univ California Diarylthiohydantoin compounds.
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CA2703780A1 (en) * 2007-10-29 2009-05-07 Takeda Pharmaceutical Company Limited Drug for prophylaxis or treatment of cancer

Also Published As

Publication number Publication date
CA2836277A1 (en) 2012-11-22
JP2014513730A (en) 2014-06-05
WO2012158884A1 (en) 2012-11-22
TW201309291A (en) 2013-03-01
EP2709614A4 (en) 2015-04-15
EP2709614A1 (en) 2014-03-26
AR086444A1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
UY34078A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER
BR112013028281A2 (en) nampt inhibiting compounds and compositions
CL2015001157A1 (en) Compositions and methods to treat proteinopathies.
CL2018003282A1 (en) Methods and compositions for the treatment of cancers resistant to inhibitors of the non-erk mapk pathway
CO6900118A2 (en) Methods to treat cancer by the use of pk-1e-binding antagonists and mek inhibitors
UY34822A (en) COMPOSITIONS AND METHODS TO SILENCE GENETIC EXPRESSION
CO7111289A2 (en) Metalloenzyme inhibitor compounds
CL2015001392A1 (en) Compounds and their methods of use
BR112013025006A2 (en) compositions and methods for inhibiting tmprss6 gene expression
BR112014001440A2 (en) New Compositions and Methods for the Treatment of Prostate Cancer
HUE048876T2 (en) Treatment of cancer
PL2739153T3 (en) TREATMENT OF NUTC CANCER
CO7020912A2 (en) Bromodomain Inhibitors
ES2579990T8 (en) Methods and compositions to treat metabolic syndrome
BR112014011009A2 (en) dual met and vegf inhibitor to treat cancer
PL2704737T3 (en) Therapeutic nuclease compositions and methods
BR112014006419A2 (en) Methods to Treat a Cancer Patient, Kit and Article
MX372754B (en) METHODS AND COMPOSITIONS RELATED TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER.
CO7151512A2 (en) Nampt inhibitors
PL2830654T3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION
HRP20182043T8 (en) THE USE OF ANTI-CONEXIN MEANS TO IMPROVE THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITOR
MX2015003701A (en) COMPOSITIONS FOR TREATMENT.
BR112013008528A2 (en) Methods To Treat Psoriasis
BR112014026326A2 (en) composition for treatment of metabolic disorders
IL239602A0 (en) Compositions and methods for intradermal delivery of non-steroidal anti-inflammatory agents

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019